Matrix metalloproteinase and tissue inhibitor of metalloproteinase (MMP/TIMP)

Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases that play a central role in the degradation and remodeling of the extracellular matrix (ECM) (Nagase et al., 2006, Cardiovascular Research). Their proteolytic activity is naturally regulated by endogenous tissue inhibitors of metalloproteinases (TIMPs), which bind to the active site of MMPs in a 1:1 stoichiometry (Brew & Nagase, 2010, Biochimica et Biophysica Acta). This balance is essential for normal physiological processes such as wound healing, angiogenesis, and embryonic development (Page-McCaw et al., 2007, Nature Reviews Molecular Cell Biology). However, an imbalance between MMPs and TIMPs is associated with various diseases, most notably cancer progression and metastasis, where excessive MMP activity facilitates basement membrane degradation and tumor cell invasion (Egeblad & Werb, 2002, Nature Reviews Cancer). Therapeutic strategies have primarily focused on developing small-molecule MMP inhibitors (MMPIs), though many early candidates like marimastat failed in clinical trials due to significant safety concerns, including musculoskeletal syndrome (Vandenbroucke & Libert, 2014, Nature Reviews Drug Discovery). Modern research continues to explore more selective inhibitors and the therapeutic potential of TIMPs themselves to restore homeostatic ECM environments (Dufour & Overall, 2013, Nature Reviews Cancer).

Other names

MatrixinsMMPsTIMPsMatrix metallopeptidasesTissue inhibitors of metalloproteinasesEndopeptidases

Inhibition of proteolytic activity through zinc-binding groups that coordinate with the catalytic zinc ion in the enzyme active site.